Hans Joachim Langmann speaking at the Annual General Meeting in 2000
Langmann has been a member of the Family Board since 1961. After positions as Supervisory Board member, personally liable general partner and Chairman of the Board of Partners, Vice Chairman of the Executive Board of E. Merck AG, Darmstadt, Germany, he becomes Chairman of the Executive Board in 1972
2001: The brand needs a new, uniform design
Continued expansion since the public offering and greater public interest prompt the redesign of the brand. A major objective is to visually harmonize the different brand designs used by subsidiaries and affiliates all over the world.
Erbitux marks our successful entry into targeted anticancer therapy
In the 1980s, the foundations for the oncology research are laid. In 2003, Erbitux is approved for the treatment of colorectal cancer. The rights to the active ingredient, the monoclonal antibody cetuximab, were acquired from ImClone in 1998. The registration dossier encompasses thousands of pages.
In 2007, the production of the oncology drug Erbitux begins at the Biotech Center
When the production of the monoclonal antibody cetuximab begins in Corsier-sur-Vevey on Lake Geneva, the topic of biotechnology is not new. The multiple sclerosis drug Rebif is one of several drugs produced here by Serono since 1999.
In 2003, the German Future Prize goes to Darmstadt
The prize is awarded to three Darmstadt-based scientists from the Liquid Crystals research unit. Vertical alignment (VA) technology makes it possible for the first time to produce flat very fast, energy-saving and large-format LC television displays.
New liquid crystal production unit
In 2004, the world’s most modern liquid crystal production unit is inaugurated in Darmstadt following a total investment of approximately € 250 million.